.jpg "web_promo_1020x536_endo_2026(2).jpg")
Adults using GLP-1 receptor agonists for weight loss experience a measurable decline in physical activity, according to a study presented at the Endocrine Society’s annual meeting. Researchers found that patients’ daily step counts dropped from an average of 5,047 to 4,487, while moderate-to-vigorous physical activity fell from 28 to 22 minutes per day, highlighting a critical risk of muscle mass loss during treatment.
Why does physical activity decrease during GLP-1 treatment?
Weight loss from medications like semaglutide, liraglutide, dulaglutide, and tirzepatide does not naturally trigger an increase in movement, according to study lead Dr. Sajana Maharjan of HSHS St. John’s Hospital. While many patients assume that losing weight will make exercise easier, the data suggests the opposite occurs. The study, which tracked 753 adults with obesity through the National Institutes of Health’s All of Us Research Program, found no evidence that the medication-induced weight loss led to a more active lifestyle. Researchers noted that the largest declines in activity occurred among men and individuals reporting existing joint or muscle pain.
This research marks the first large-scale analysis of wearable fitness tracker data among patients using GLP-1 medications. By linking electronic health records with Fitbit data, investigators were able to track real-world behavior rather than relying on self-reported surveys.
How does muscle loss impact long-term health?
GLP-1 receptor agonists reduce both fat and lean muscle mass, according to Dr. Maharjan. Because muscle is essential for maintaining strength and metabolic health, a sedentary lifestyle during weight loss can lead to sarcopenia—the loss of muscle mass and function. While heart failure, stroke history, and age did not influence the decline in activity, the reduction in movement leaves patients vulnerable to muscle atrophy. Clinical experts emphasize that exercise must remain a non-negotiable component of a weight-management plan, rather than an optional activity, to ensure that the weight lost is primarily fat rather than vital muscle tissue.
What are the future trends for GLP-1 patient care?
The medical community is shifting toward “targeted interventions” to combat the sedentary trend associated with these drugs. Future clinical protocols will likely pair medication with structured exercise programs to protect lean mass. As wearable technology becomes standard in clinical research, doctors can monitor patient activity levels more accurately to provide personalized feedback. The findings from the Endocrine Society’s meeting suggest that prescriptions for obesity should increasingly include specific requirements for physical activity to counteract the natural tendency toward lower movement levels after starting treatment.
If you are currently taking a GLP-1 medication, don’t wait for your energy levels to change on their own. Set a daily step goal and use a wearable device to track your activity. Consult your physician about resistance training exercises that can help you preserve muscle mass while you lose weight.
Frequently Asked Questions
Does weight loss from GLP-1s lead to more exercise?
No. According to the study presented at ENDO 2026, patients actually decreased their daily step counts and moderate-to-vigorous activity minutes after beginning the medication.
Why is muscle mass a concern during weight loss?
GLP-1 medications reduce both fat and lean muscle. Losing muscle can lead to weakness and reduced metabolic function, making regular strength training essential, according to Dr. Sajana Maharjan.
Who is most at risk for reduced activity while on these drugs?
The study found that men and individuals with existing joint or muscle pain showed the most significant declines in physical activity after starting treatment.
Are you currently managing your health with GLP-1 medications? We want to hear about your experience. Share your thoughts on balancing medication with physical activity in the comments below, or subscribe to our newsletter for the latest updates on metabolic health research.
